Xihang Chen

Xihang Chen

Auto-generated profile, based on publicly available information

Xihang Chen

Health Data Sciences Group, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, United Kingdom

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2024
Verified
Dataset
Closed access
EBEdward Burn
Edward Burn
MCMartí Català
Martí Català
NMNuria Mercade-Besora
Nuria Mercade-Besora
MAMarta Alcalde
Marta Alcalde
MDMike Du
Mike Du
ERElin Rowlands
Elin Rowlands

12 September 2025 in Journal of Open Source Software
Verified
Journal Article
Open access
PDF file
MDMike Du
Mike Du
NMNúria Mercadé-Besora
Núria Mercadé-Besora
MAMarta Alcalde
Marta Alcalde
XCXihang Chen
Xihang Chen
YGYuchen Guo
Yuchen Guo
MCMartí Català
Martí Català
Package provides a flexible and efficient way to create synthetic datasets in OMOP CDM format, facilitating the testing and validation of packages and analytic codes.

7 February 2023
Verified
Dataset
Closed access
EBEdward Burn
Edward Burn
MAMarta Alcalde
Marta Alcalde
MCMartí Català
Martí Català
XCXihang Chen
Xihang Chen
NMNuria Mercade-Besora
Nuria Mercade-Besora
DNDanielle Newby
Danielle Newby



17 November 2025 in medRxiv
Verified
Preprint
Open access
PDF file
XCXihang Chen
Xihang Chen
TSTyman Stanford
Tyman Stanford
YGYuchen Guo
Yuchen Guo
BRBerta Raventós
Berta Raventós
MDMike Du
Mike Du
DNDanielle Newby
Danielle Newby
Background: Real-world data are valuable for detecting adverse drug events, and Sequence Symmetry Analysis (SSA) is a simple yet effective method frequently used for this purpose. However, heterogeneous implementations across studies limit reproducibility and scalability. To address this, we developed an open-source R package that standardises SSA analytics using data mapped to the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM). Methods: We developed CohortSymmetry , an R package that implements SSA for OMOP CDM data. The package was validated through unit testing and evaluated empirically by estimating adjusted sequence ratios (ASRs) with 95% confidence intervals (CIs) for 23 positive and 10 negative controls across six European databases, including CPRD GOLD (UK) and THIN® (Belgium, Italy, Romania, Spain, UK). Sensitivity and specificity were defined as the proportions of positive and negative controls correctly identified by SSA. Sensitivity analyses varied key parameters, including the washout period. Results: CohortSymmetry passed high-coverage unit tests. Of 33 eligible controls, four showed results consistent with expectations across all databases; for example, the amiodarone–levothyroxine pair had a lower 95% CI bound >1 in each. Sensitivity was moderate, whereas specificity was high in the primary analyses. Parameter variation influenced outcomes; a 365-day prior observation requirement reduced specificity in CPRD GOLD from 75% to 38%. Conclusions: CohortSymmetry enables reproducible SSA using OMOP CDM data. Differences across databases likely reflect heterogeneity in data capture and prescribing patterns. Limitations include residual data variability and SSA’s susceptibility to time-varying confounding, underscoring the need for tailored analytic design in pharmacovigilance studies. Key Messages: We developed CohortSymmetry, an open-source R package that standardises SSA analytics using OMOP CDM-mapped data and verified the correctness of functions via unit testing and application to real-world datasets. CohortSymmetry passed high-coverage tests, and among 33 selected controls, four showed results consistent with expectations across all databases; varying analytical parameters affected results. The package provides a reproducible and scalable framework for multi-database SSA studies, supporting robust pharmacovigilance, but careful specification of parameters is required to account for the characteristics of the medical domain under investigation.